We recently published a list of Why These 10 Stocks Soared Today. In this article, we are going to take a look at where Elanco Animal Health Incorporated (NYSE:ELAN) stands against other Wednesday’s best-performing stocks. The stock market rebounded on Wednesday, with all major indices ending in the green as investors cheered the Federal Reserve’s decision to keep interest rates unchanged. On Wednesday afternoon, the Fed kept rates steady at a range of 4.25 percent to 4.5 percent, saying that it was not in a hurry to cut rates and could still “wait and see” the impact of President Donald Trump’s tariff policies. The Dow Jones rallied by 0.70 percent, the S&P 500 increased by 0.43 percent, and the Nasdaq grew by 0.27 percent. Beyond the major indices, 10 firms stood out with strong gains, thanks to a flurry of fresh developments, including new partnerships, optimistic outlooks, and impressive earnings performance. In this article, we name Wednesday’s 10 best-performing stocks and detail the reasons behind their gains. To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume.Why Elanco Animal Health Incorporated (ELAN) Skyrocketed On Wednesday A farmer tending to a herd of cattle with Innovative Parasiticide and Vaccine Products. Elanco Animal Health Incorporated (NYSE:ELAN) Elanco Animal Health saw its share prices soar by 26.29 percent on Wednesday to end at $12.01 apiece following an impressive net income performance coupled with an optimistic outlook for the rest of the year. In its latest earnings release, Elanco Animal Health Incorporated (NYSE:ELAN) said net income for the first quarter of the year expanded by 109 percent to $67 million from $32 million in the same period last year, despite total revenues dipping by 1 percent to $1.19 billion from $1.2 billion year-on-year, weighed down by an unfavorable impact from the aqua divestiture coupled with foreign exchange losses during the quarter. Despite this, Elanco Animal Health Incorporated (NYSE:ELAN) remains optimistic for the rest of the year, having raised its revenue guidance to a range of $4.51 billion to $4.58 billion. Net loss, on the other hand, is expected to widen to a range of $7 million to $35 million. “We are raising our 2025 full-year revenue guidance and maintaining our adjusted EBITDA and adjusted EPS ranges,” said CFO Todd Young. “On tariffs, we have taken several intervention actions, positioning us well to cover potential impacts with or without the pharmaceutical exemption,” he added. Overall, ELAN ranks 2nd on our list of Wednesday’s best-performing stocks. While we acknowledge the potential of ELAN as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ELAN but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. Story Continues READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. View Comments
Why Elanco Animal Health Incorporated (ELAN) Skyrocketed On Wednesday
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...